“…To inform the MOA and risk assessment of oral Cr(VI) exposure, a series of studies were conducted beginning with an overall proposed MOA (Thompson, Haws, Harris, Gatto, & Proctor, 2011), and subsequent 90‐day toxicity studies (Thompson, Proctor, et al, 2011; Thompson et al, 2012), transcriptomic analyses (Kopec et al, 2012; Kopec, Thompson, Kim, Forgacs, & Zacharewski, 2012; Rager et al, 2017), genotoxicity studies (O'Brien et al, 2013; Thompson, Seiter, et al, 2015; Thompson, Wolf, et al, 2015; Thompson, Young, et al, 2015; Thompson et al, 2017), as well as ex vivo gastric reduction studies and pharmacokinetic modeling (De Flora et al, 2016; Kirman et al, 2012; Kirman et al, 2013; Kirman et al, 2016; Proctor et al, 2012). Other genotoxicity studies were conducted in response to early drafts of the NTP 2‐year cancer bioassay (De Flora et al, 2006; De Flora et al, 2008).…”